ArticleJournal of translational medicine2025
SLC16A3 as an immunosuppressive Kupffer cell marker predicts poor prognosis in HBV-positive hepatocellular carcinoma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SLC16A3 links tumor metabolism to therapeutic opportunities in hepatocellular carcinoma.Translational cancer research · 2026Review
- Virus infections and cancers: from mechanisms to therapeutics.Molecular biomedicine · 2026Review
- Lactate-lactylation in tumor angiogenesis and progression: mechanisms, biomarker potential, and therapeutic implications.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the malignant tumors that currently pose a significant threat to human health, with infection by hepatitis B virus (HBV) being a critical risk factor for the development of HCC. It is critical to identify potential molecular targets affecting HBV-positive HCC patients.
methodsIn this study, we comprehensively utilized single-cell sequencing and external transcriptome sequencing databases to further analyze the mechanism of SLC16A3's influence on liver cancer and its microenvironment under different HBV status. Immunohistochemical staining in our clinical cohort was used to analyze the expression difference and influence of SLC16A3 in HCC. At the same time, we confirmed the direct effects of SLC16A3 on HCC cells with different HBV status through cell line experiments.
resultsCompared with normal tissues, SLC16A3 expression is up-regulated in HBV-positive HCC patients, and the up-regulation amplitude is greater than that in HBV-negative HCC patients, and it is associated with poor prognosis. The validation was performed on several external validation data sets and external validation queues. Multi-omics analysis showed that SLC16A3 expression is related to the specific differentiation of the immune microenvironment, especially Kupfer cells, which can mediate the emergence of the inhibitory immune microenvironment and indirectly lead to poor prognosis. SLC16A3 can directly mediate the proliferation of HBV-positive liver cancer cell lines in vitro.
conclusionOur study found that SLC16A3 is closely related to HBV status and liver cancer, and it has a significant marker for the prognosis of HBV-positive liver cancer. SLC16A3 is associated with abnormal metabolic pattern and immune regulation of Kupffer cells, and can directly affect HBV-positive hepatocellular carcinoma cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.